Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors.
This study investigated the reciprocal cross-interactions between two distinct allosteric sites on the M(4) muscarinic acetylcholine receptor (mAChR) in the absence or presence of different orthosteric ligands. Initial studies revealed that two novel benzimidazole allosteric modulators, 17-beta-hydroxy-17-alpha-ethy nyl-delta(4)-androstano[3,2-b]pyrimido[1,2-a]benzimidazole (WIN 62,577) and 17-beta-hydroxy-17-alpha-ethynyl-5-alpha-androstano[3,2-b]pyrimido[1,2-a]benzimidazole (WIN 51,708), exhibited different degrees of positive, negative, or close-to-neutral cooperativity with the orthosteric site on M(1) or M(4) mAChRs, depending on the chemical nature of the orthosteric radioligand that was used [[(3)H]N-methylscopolamine ([(3)H]NMS) versus [(3)H]quinuclidinylbenzilate ([(3)H]QNB)]. The largest window for observing an effect (negative cooperativity) was noted for the combination of WIN 62,577 and [(3)H]QNB at the M(4) mAChR. Experiments involving the combination of these two ligands with unlabeled agonists [acetylcholine, 4-(m-chlorophenylcarbamoyloxy)-2-butynyltrimethylammonium (McN-A-343), or xanomeline] revealed low degrees of negative cooperativity between WIN 62,577 and each agonist, whereas stronger negative cooperativity was observed against atropine. It is interesting that when these experiments were repeated using the prototypical modulators heptane-1,7-bis-(dimethyl-3'-phthalimidopropyl)-ammonium bromide (C(7)/3-phth), alcuronium, or brucine (which act at a separate allosteric site), WIN 62,577 exhibited negative cooperativity with each modulator when the orthosteric site was unoccupied, but this switched to neutral cooperativity when the receptor was occupied by [(3)H]QNB. Dissociation kinetic experiments using [(3)H]NMS and combination of C(7)/3-phth with WIN 62,577 also provided evidence for neutral cooperativity between the two allosteric sites when the orthosteric site is occupied. Together, these results provide insight into the nature of the interaction between two distinct allosteric sites on the M(4) mAChR and how this interaction is perturbed upon occupancy of the orthosteric site.
Lanzafame
Alfred A
AA
Drug Discovery Biology Laboratory, Department of Pharmacology, Building 13E, Monash University, Clayton 3800, Victoria, Australia.
Sexton
Patrick M
PM
Christopoulos
Arthur
A
D000495:Allosteric Site; D000731:Androstanes / Q000494:pharmacology; D000736:Androstenes / Q000494:pharmacology; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D016466:CHO Cells; D006224:Cricetinae; D006801:Humans; D019832:N-Methylscopolamine / Q000378:metabolism; D011813:Quinuclidinyl Benzilate / Q000378:metabolism; D043643:Receptor, Muscarinic M1 / Q000378:metabolism; D043588:Receptor, Muscarinic M4 / Q000737:chemistry / Q000378:metabolism*
D000731:Androstanes; D000736:Androstenes; D001562:Benzimidazoles; D043643:Receptor, Muscarinic M1; D043588:Receptor, Muscarinic M4; C086111:WIN 51708; C086110:WIN 62577; D011813:Quinuclidinyl Benzilate; D019832:N-Methylscopolamine